Prokidney Corp. (PROK): Capital Expenditures
$15.20M
Year ended 2025-12-31
$18.57M
Trailing 12 months to 2026-06-30
+101.9%
3-year compound annual growth
+22.7%
5-year compound annual growth
| Period ended | Capital Expenditures | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $15.20M | -48.5% | 2026-03-18, From 2025-01-01 |
| 2024-12-31 | $29.51M | -13.7% | 2026-03-18, From 2024-01-01 |
| 2023-12-31 | $34.20M | n/m | 2026-03-18, From 2023-01-01 |
| 2022-12-31 | $1.85M | -64.4% | 2025-03-17, From 2022-01-01 |
| 2021-12-31 | $5.19M | -4.8% | 2024-03-22, From 2021-01-01 |
| 2020-12-31 | $5.46M | n/a | 2023-03-28, From 2020-01-01 |
Capital Expenditures at similar companies
| Company | Year ended | Capital Expenditures | Change YoY |
|---|---|---|---|
| Prokidney Corp. (PROK) | 2025-12-31 | $15.20M | -48.5% |
| Pluri Inc. (PLUR) | 2026-06-30 | $633.0K | -60.9% |
| Inhibrx Biosciences, Inc. (INBX) | 2025-12-31 | $31.0K | -98.8% |
| Scinai Immunotherapeutics Ltd. (SCNI) | 2025-12-31 | $24.0K | +100.0% |
| Cardiff Oncology, Inc. (CRDF) | 2025-12-31 | $44.0K | -45.0% |
| Humacyte, Inc. (HUMA) | 2025-12-31 | $884.0K | -43.8% |
| Aligos Therapeutics, Inc. (ALGS) | 2024-12-31 | $130.0K | +584.2% |
| Surrozen, Inc. (SRZN) | 2025-12-31 | $128.0K | +392.3% |
| CRISPR Therapeutics AG (CRSP) | 2025-12-31 | $914.0K | -51.9% |
Compare PROK, PLUR, INBX, SCNI side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗